Eli Lilly restructuring affects CME

In a press release on insideindianabusiness.com, Eli Lilly announced that it was cutting 575 positions and restructuring many of its departments.

    Parts of the business-to-business (B2B) unit and U.S. medical division will be restructured to gain efficiencies. The B2B organization, for example, will resize its public health division as well as strategic marketing and customer business solution functions. U.S. medical will restructure clinical operations, reduce medical liaison support, and centralize regulatory activities and implement cost improvement measures in areas such as new clinical trials and continuing medical education. (Emphasis added.)

I'm not sure exactly what that means, but if you work for or with Eli Lilly, it sounds like some changes are coming your way, and they may involve some belt-tightening.

To comment on this post, click on "comments" below. To receive a weekly update, e-mail Sue.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.